A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Must have received: standard therapeutic regimen

Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants must be relapsed or refractory to, have developed an intolerance to, or not be candidates for available therapies with established benefit.

Must have received: standard therapy for B-cell malignancies

Participants with B-cell malignancies should have received at least two lines of therapy, including available therapies with established benefit.

Must have received: standard therapy for SLL

Participants with SLL should have received at least three prior lines of therapy.

Cannot have received: antibody-drug conjugate with topoisomerase-1 inhibitor payload

Exception: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload.

Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload.

Cannot have received: ROR1-targeted therapy

Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody).